A translational MRI approach to validate acute axonal damage detection as an early event in multiple sclerosis
eLife · 2024
DOI: 10.7554/elife.79169 ↗Kurz gefasst
Fachartikel in der Zeitschrift eLife, 2024. Verfasst von Antonio Cerdán Cerdá und 8 weiteren Autor:innen. Beteiligte Einrichtung: Instituto de Neurociencias de Alicante, CSIC-UMH, San Juan de Alicante, Spain. Hauptthemen laut MEDLINE: Multiple Sclerosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NINDS NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Axonal degeneration is a central pathological feature of multiple sclerosis and is closely associated with irreversible clinical disability. Current noninvasive methods to detect axonal damage in vivo are limited in their specificity and clinical applicability, and by the lack of proper validation. We aimed to validate an MRI framework based on multicompartment modeling of the diffusion signal (AxCaliber) in rats in the presence of axonal pathology, achieved through injection of a neurotoxin damaging the neuronal terminal of axons. We then applied the same MRI protocol to map axonal integrity in the brain of multiple sclerosis relapsing-remitting patients and age-matched healthy controls. AxCaliber is sensitive to acute axonal damage in rats, as demonstrated by a significant increase in the mean axonal caliber along the targeted tract, which correlated with neurofilament staining. Electron microscopy confirmed that increased mean axonal diameter is associated with acute axonal pathology. In humans with multiple sclerosis, we uncovered a diffuse increase in mean axonal caliber in most areas of the normal-appearing white matter, preferentially affecting patients with short disease duration. Our results demonstrate that MRI-based axonal diameter mapping is a sensitive and specific imaging biomarker that links noninvasive imaging contrasts with the underlying biological substrate, uncovering generalized axonal damage in multiple sclerosis as an early event.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Instituto de Neurociencias de Alicante, CSIC-UMH, San Juan de Alicante, Spain.
- Athinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, United States.
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
- Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL), Alicante, Spain.
- Millennium Nucleus for the Study of Pain (MiNuSPain), Santiago, Chile.
ORCID-Profile: Antonio Cerdán Cerdá, Jose A Gomez-Sanchez, Silvia De Santis
Förderung
- NINDS NIH HHS
- NIH HHS
- National Institutes of Health
- Agencia Estatal de Investigación
- Ministry of Science, Innovation and Universities
- Generalitat Valenciana
- Instituto de Salud Carlos III
Zitieren
APA
Cerdán Cerdá, A., Toschi, N., Treaba, C. A., Barletta, V., Herranz, E., Mehndiratta, A., Gomez-Sanchez, J. A., Mainero, C., & De Santis, S. (2024). A translational MRI approach to validate acute axonal damage detection as an early event in multiple sclerosis. eLife. https://doi.org/10.7554/elife.79169
Vancouver
Cerdán Cerdá A, Toschi N, Treaba CA, Barletta V, Herranz E, Mehndiratta A, et al. A translational MRI approach to validate acute axonal damage detection as an early event in multiple sclerosis. eLife. 2024. doi:10.7554/elife.79169
BibTeX
@article{CerdnCerd2024,
author = {Cerdán Cerdá, Antonio and Toschi, Nicola and Treaba, Constantina A and Barletta, Valeria and Herranz, Elena and Mehndiratta, Ambica and Gomez-Sanchez, Jose A and Mainero, Caterina and De Santis, Silvia},
title = {A translational MRI approach to validate acute axonal damage detection as an early event in multiple sclerosis},
journal = {eLife},
year = {2024},
doi = {10.7554/elife.79169}
}
EUVIMED